Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objectives: (1) To document rates and patterns of adherence from enrollment until week 24 of an AIDS clinical trial; (2) to examine the association of adherence to clinical end-points including plasma HIV-1 RNA level and CD4 cell count; and (3) to identify predictors of adherence from clinical, behavioural, psychosocial and demographic factors. Design: Sub-study of a multicentre, randomised, open-label, comparison-controlled trial; 21 collaborating units of the Adult AIDS Clinical Trials Group. Observational, prospective analysis. Methods: Ninety-three subjects with baseline plasma HIV-1 RNA levels >500 copies/ml, who completed clinical assessment, plasma HIV-1 RNA titres and CD4 cell counts at study entry, weeks 2, 4 and every 4 weeks thereafter until week 24. All patients were antiretroviral-experienced but were naive to non-nucleoside reverse transcriptase inhibitors and protease inhibitors. Self-reported adherence to antiretroviral therapies prescribed as part of the trial was assessed every 4 weeks from trial, week 4 until week 24. Results: Average adherence was high, with 63% of subjects reporting >95% adherence across the trial. However, there was a significant decline in adherence over time on trial. After controlling for potential confounding variables, patients who were less than 95% adherent to medications were 3.5-times more likely to have treatment failure (HIV-1 RNA >50 copies/ml) than subjects with adherence rates of 95–100%. The strongest predictor of adherence was adverse clinical events (for example, dermatological, gastrointestinal symptoms): patients with adverse events were 12.8-times less likely to have 95–100% adherence. Other clinical, demographic, psychosocial and behavioural factors were also significant predictors of adherence. Conclusions: Adherence influences virological outcome even in AIDS clinical trials where overall adherence rates are high and should therefore be monitored in future trials. Intervention may be warranted to enhance adherence for subjects who have early toxicities, express concern about taking medications as directed, and for women and minorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chesney, M. A., Ickovics, J. R., Chambers, D. B., Gifford, A. L., Neidig, J., Zwickl, B., Wu, A. W., & PATIENT CARE COMMITTEE & ADHERENCE (2000) · AIDS Care · doi:10.1080/09540120050042891 · Cited by 1,428 · cited 1×
“For each antiretroviral drug prescribed as part of the clinical trial, subjects reported the number of pills skipped on each of 4 days prior to each study visit [33].”
BackgroundSelf-citationMontaner, J. S. G., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B., Wainberg, M. A., Smith, D., Robinson, P., Hall, D., et al. (1998) · JAMA · doi:10.1001/jama.279.12.930 · Cited by 756
Measuring Stress: A Guide for Health and Social Scientists
(1995) · doi:10.1093/oso/9780195086416.001.0001 · Cited by 346
Cited by
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Simoni, J. M., Kurth, A. E., Pearson, C. R., Pantalone, D. W., Merrill, J. O., & Frick, P. A. (2006) · AIDS and Behavior · doi:10.1007/s10461-006-9078-6 · Cited by 653
Langebeek, N., Gisolf, E. H., REISS, P. C., Vervoort, S. C. J. M., Hafsteinsdøttir, T. B., Richter, C., Sprangers, M. A. G., & Nieuwkerk, P. T. (2014) · BMC Medicine · doi:10.1186/preaccept-1453408941291432 · Cited by 405
Langebeek, N., Gisolf, E. H., Reiss, P., Vervoort, S. C., Hafsteinsdóttir, T. B., Richter, C., Sprangers, M. A., & Nieuwkerk, P. T. (2014) · BMC Medicine · doi:10.1186/s12916-014-0142-1 · Cited by 394
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dubé, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030264 · Cited by 351
Self-citation
Metadata
- Authors
- Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., Kuritzkes, D. R., ACTG 370 Protocol Team, Adult AIDS Clinical Trials Group protocol 370, Acosta, E., Barnett, R., Bell, D., Cannmann, S., Eron, J., Fischl, M., Marschner, I., Martinez, A., Morse, G., Pettinelli, C., Sommadossi, J.-P., Wood, K., Murphy, R., Priller, N., Sha, B., French, N., van der Horst, C., Marcus, C., Lane, T., Horton, J., Schooley, R., Putnam, B., Shugarts, D., Johnson, S., Fife, K., Black, J., Heise, D., Todd, K., Bagur, J. S., Vazquez, G., Lopez, I., Ramirez, V, Hill, R., Wright, S., McCulloch, B., Saag, M., Slamowitz, D., Cain, P., Merigan, T., Tallman, V, Greisberger, C., Shoemaker, M., Lewis, M., Hewitt, R., Havlir, D., Nuffer, K., Wininger, D., Watson, S., Clark, J., Jackson, C., Rodriguez, A., Scerpella, E., Tebas, P., Stiffler, T., Royal, M., Powderly, W., Collier, A., Storey, S., Houseworth, L., Conley, N., Lederman, M., Kalayjian, B., Ingersol, K., McVey, R., Gluckman, S., Helker, C., Kappes, R., Kim, D., Albrecht, M., Koziol, C., Govan;, T., Miles, S., Chafey, S., Mitsuyasu, R., Sacks, H., Mildvan, D., Shikuma, C., Millard, M., & Souza, S.
- Venue
- Antiviral Therapy
- Publisher
- SAGE Publications
- Published
- 2002-04
- Volume
- 7
- Issue
- 3
- Pages
- 185-193
- ISSN
- 1359-6535 (ISSN-L)
- 2040-2058
- OpenAlex
- W914135345
- Cited by
- 128
- References
- 3
- FWCI
- 5.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370. https://app.cochat.ai/papers/10.1177/135965350200700308
- The paper
- Ickovics, J. R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V. A., Kuritzkes, D. R., ACTG 370 Protocol Team, Adult AIDS Clinical Trials Group protocol 370, Acosta, E., Barnett, R., Bell, D., Cannmann, S., Eron, J., Fischl, M., Marschner, I., Martinez, A., Morse, G., Pettinelli, C., . . . Souza, S. (2002). Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370. Antiviral Therapy. https://doi.org/10.1177/135965350200700308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.